Renal bone disease

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 6, 2010, Pages 535-539

  Sprague, Stuart M ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

adynamic bone disease; chronic kidney disease mineral and bone disorder; hyperparathyroidism; osteitis fibrosa

Indexed keywords

CALCITRIOL; CALCIUM; DOXERCALCIFEROL; PARICALCITOL; PHOSPHATE BINDING AGENT;

BONE BIOPSY; BONE DISEASE; BONE STRUCTURE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; MINERAL METABOLISM; MORBIDITY; OSTEITIS FIBROSA; OSTEOMALACIA; PATHOLOGY; PERITONEAL DIALYSIS; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; VITAMIN D DEFICIENCY;

BONE AND BONES; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY;

EID: 78649290986     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283400945     Document Type: Review

References (30)

1. Moe S, Drueke T, Cunningham J. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953.
2. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333:166-174.
3. Juppner H, Wolf M, Salusky IB. FGF23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010 [Epub ahead of print].
4. Sherrard DJ, Hercz G, Pei Y. Thespectrum of bonedisease in end-stagerenal failure: an evolving disorder. Kidney Int 1993; 43:436-442.
5. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009:S1-S130.
6. Gal-Moscovici A, Sprague SM. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis 2007; 14:27-36. (Pubitemid 46019904)
7. Gal-Moscovici A, Sprague SM. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2008; 3 (Suppl 3):S170-S174.
8. Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002; 22:488-493.
9. Levin A, Bakris GL, Molitch M. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38.
10. Craver L, Marco MP, Sarro F. Mineral metabolism parameters throughout chronic kidney disease stages 1-5: achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007; 22:1171-1176.
11. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63:284-289.
12. Bervoets AR, Spasovski GB, Behets GJ. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure pa-tients. Am J Kidney Dis 2003; 41:997-1007.
13. Spasovski GB, Bervoets AR, Behets GJ. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 2003; 18:1159-1166.
14. Coen G, Mantella D, Manni M. 25-hydroxyvitamin D levels and bone histo-morphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68:1840-1848.
15. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73:1345-1354.
16. Alikhani M, Alikhani Z, Boyd C. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40:345-353.
17. Mucsi I, Hercz G. Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 1999; 317:405-409.
18. Slatopolsky E, Finch J, Clay P. A novel mechanism for skelet al resistance in uremia. Kidney Int 2000; 58:753-761.
19. Parkinson IS, Ward MK, Kerr DN. Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis. J Clin Pathol 1981; 34:1285-1294.
20. Kanis JA, Brown CB, Cameron EC The role of vitamin D metabolites in the osteomalacia of renal disease. Curr Med Res Opin 1981; 7:294-315.
21. Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin JAm Soc Nephrol 2008; 3 (Suppl 3): S157-S163.
22. Torres A, Lorenzo V, Hernandez D. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47:1434-1442.
23. Souberbielle JC, Boutten A, Carlier MC. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70:345-350.
24. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 2007; 23:3167-3175.
25. Sherman RA, Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis 2009; 54:18-23.
26. Sprague SM, Ross EA, Nath SD. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009; 72:252-258.
27. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int 2010; 78:146-151.
28. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:512-518.
29. Andress DL, Coyne DW, Kalantar-Zadeh K. Management of secondary hyper-parathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract 2008; 14:18-27.
30. Sprague SM, Evenepoel P, Curzi MP. Simultaneous control of PTH and CaxP is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009; 4:1465-1476.